USA flag logo/image

An Official Website of the United States Government

Ultraviolet B Irradiation of Allogeneic Veins

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
22332
Program Year/Program:
1993 / SBIR
Agency Tracking Number:
22332
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
CRYOLIFE, INC.
1655 ROBERTS BLVD, NW KENNESAW, GA 30144
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1993
Title: Ultraviolet B Irradiation of Allogeneic Veins
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

The major factor limiting more widespread utilization of allogeneic veins in arterial bypass procedures is the recipients' immune response. The intimal endothelial cells appear to be the focus of this immune response, which results in loss of the intimal lining of the vessel lumen during the first two weeks after transplantation and the longer-term risk of occlusion. This proposal will examine the hypothesis that ultraviolet B (UVB) irradiation may reduce the immunostimulatory capabilities of allogeneic canine saphenous veins, while preserving cell viability. Initial in vitro experiments will determine whether UVB irradiation of endothelial cells can induce immunological tolerance in mixed cultures of irradiated endothelial cells and non-irradiated allogeneic peripheral blood mononuclear cells. In situ experiments will then be performed, using UVB doses defined in vitro, to select a dose with maximal in vitro effect and minimal in situ losses of cell viability. An in vivo transplantation study will then be performed to determine the effects of this selected UVB irradiation dose on endothelial cell survival and allograft patency. If the results of this feasibility study are positive, human saphenous veins will be studied in the next, Phase II, grant application. Reduction of the immunological consequences of venous allografting would justify the use of allograft veins in a broad range of clinical applications.

Principal Investigator:

Kelvin G. Brockbank
4049521660

Business Contact:

Small Business Information at Submission:

Cryolife, Inc.
2211 New Market Parkway, Suite Marietta, GA 30067

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No